Press Releases

Date Title  
Toggle Summary Nuvectra® to Participate in Two Upcoming Investor Conferences
PLANO, Texas , June 12, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that members of management are scheduled to participate in two upcoming investor conferences in New York, NY .                             Event:        
Toggle Summary Nuvectra Files Regulatory Submission with FDA for Algovita® Full-Body MR-Conditional Approval
PLANO, Texas , June 11, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it has filed its regulatory submission with the U.S. Food and Drug Administration ( FDA ) for full-body MR-conditional approval for the Company’s
Toggle Summary Nuvectra Highlights Positive Preliminary Algovita® Clinical Data at the INS 14th Annual World Congress
Data Illustrates Below Industry Average Lead Fracture and Migration Rates PLANO, Texas ,, May 30, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today preliminary Algovita ® clinical data from its U.S.
Toggle Summary Nuvectra® Announces Departure of COO & CFO Walter Z. Berger
Appoints Jennifer Kosharek as Interim CFO PLANO, Texas , May 16, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, today announced that Walter Z. Berger has resigned as Nuvectra’s Chief Operating Officer and Chief Financial Officer to pursue
Toggle Summary Nuvectra® Reports First Quarter 2019 Financial Results
PLANO, Texas , May 01, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the first quarter ended March 31, 2019 . Recent Business Highlights Increased Algovita ® revenues 22% YoY to $11.0 million Providing
Toggle Summary Nuvectra to Report First Quarter 2019 Financial Results on May 1, 2019
PLANO, Texas , April 22, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the first quarter ended March 31, 2019 on Wednesday, May 1, 2019 after market close.
Toggle Summary Nuvectra® Appoints Anthony P. Bihl, III as New Chairman of the Board
Elects Jane J. Song to the Board of Directors PLANO, Texas , March 25, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, today announced the appointment of Anthony P. Bihl, III as Chairman of the Board of Directors, following Dr. Joseph A.
Toggle Summary Nuvectra® Reports Fourth Quarter and Full Year 2018 Financial Results
Record Fourth Quarter & Full Year 2018 Algovita® Sales of $14.1 million and $47.1 million, Up 36% and 84% YoY Respectively PLANO, Texas , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the
Toggle Summary Nuvectra® to Present at 39th Annual Cowen Healthcare Conference
PLANO, Texas , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that Fred Parks , PhD, Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to present at the
Toggle Summary Nuvectra to Report Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019
PLANO, Texas , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the fourth quarter and full year ended December 31, 2018 on Thursday, February 28, 2019 after market close.
Toggle Summary Nuvectra® Appoints Dr. Fred B. Parks as Chief Executive Officer
Elects Christopher G. Chavez as a Member of the Board of Directors PLANO, Texas , Jan. 31, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, today announced the appointment of Fred B. Parks , PhD, as Chief Executive Officer, effective
Toggle Summary Nuvectra Provides Update on Virtis™ FDA PMA Submission
PLANO, Texas , Jan. 29, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a medical device company dedicated to neuromodulation, announced today that the U.S. Food and Drug Administration ( FDA ) has advised that its review of Company’s pre-market approval (PMA) application for its
Toggle Summary Nuvectra® Announces Preliminary Unaudited Fourth Quarter and Full Year 2018 Revenue
PLANO, Texas , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2018 . Preliminary unaudited consolidated revenue in the fourth
Toggle Summary Nuvectra Announces Divesture of NeuroNexus Subsidiary
PLANO, Texas , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it has entered into an agreement effective December 31, 2018 , to sell its wholly owned subsidiary NeuroNexus Technologies, Inc.
Toggle Summary Nuvectra Receives Full-Body MR-Conditional CE Mark Approval for Algovita®
PLANO, Texas , Dec. 12, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it has received full-body MR-conditional approval for the Company’s Algovita SCS system from its European Notified Body, TÜV SÜD.
Toggle Summary Nuvectra Completes 3,000 U.S. Algovita® SCS Implantations
PLANO, Texas , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that the Company’s Algovita ® Spinal Cord Stimulation (SCS) system has been implanted in over 3,000 patients in the U.S.
Toggle Summary Nuvectra Receives FDA Head-Only MR-Conditional Approval for Algovita®
PLANO, Texas , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it has received U.S. Food and Drug Administration ( FDA ) head-only MR-conditional approval for the Company’s Algovita SCS system.
Toggle Summary Nuvectra® to Participate in Two Upcoming Investor Conferences
PLANO, Texas , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to participate in two
Toggle Summary Nuvectra® Reports Third Quarter 2018 Financial Results
Reports Record Algovita ® Sales of $12.5 million , Up 98% YoY PLANO, Texas , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the third quarter ended September 30, 2018 .
Toggle Summary Nuvectra® to Report Third Quarter 2018 Financial Results on October 29, 2018
PLANO, Texas , Oct. 22, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the third quarter ended September 30, 2018 on Monday, October 29, 2018 after market close.
Toggle Summary Nuvectra® Announces Closing of Follow-On Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
PLANO, Texas , Sept. 14, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today the closing of its underwritten follow-on public offering of 3,248,750 shares of its common stock at a price to the public of $21.25 per share, which
Toggle Summary Nuvectra® Announces Pricing of Follow-On Stock Offering
PLANO, Texas , Sept. 11, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today the pricing of its underwritten follow-on public offering of 2,825,000 shares of its common stock at a price to the public of $21.25 per share.
Toggle Summary Nuvectra® Announces Proposed Follow-On Stock Offering
PLANO, Texas , Sept. 11, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it is commencing an underwritten follow-on public offering of its common stock. In addition, Nuvectra intends to grant the underwriters a 30-day
Toggle Summary Nuvectra to Participate in Two Upcoming Investor Conferences
PLANO, Texas , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to participate in two
Toggle Summary Nuvectra™ Reports Second Quarter 2018 Financial Results
Reports Record Algovita® Sales of $11.5 million, Up 110% YoY PLANO, Texas , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the second quarter ended June 30, 2018 .
Toggle Summary Nuvectra™ Appoints Neuromodulation Veteran Ben Tranchina as Chief Technology Officer
PLANO, Texas , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today the appointment of Ben Tranchina as Chief Technology Officer (CTO), effective August 24, 2018 . Mr. Tranchina has over 25 years of industry experience and
Toggle Summary Nuvectra™ to Report Second Quarter 2018 Financial Results on August 7, 2018
PLANO, Texas , July 31, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the second quarter ended June 30, 2018 on Tuesday, August 7, 2018 after market close.
Toggle Summary Nuvectra Completes 2,000 U.S. Algovita® SCS System Implantations
PLANO, Texas , July 10, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that the Company’s Algovita® Spinal Cord Stimulation (SCS) system has been implanted in over 2,000 patients in the U.S.
Toggle Summary Nuvectra Provides Update on FDA and TÜV SÜD Review of Virtis™ PMA and CE Mark Applications
PLANO, Texas , July 02, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, today provided an update on its U.S. Food and Drug Administration ( FDA ) pre-market approval (PMA) application and its TÜV SÜD application for CE Mark in Europe for
Toggle Summary Nuvectra Added to the Russell 2000® Index
PLANO, Texas , June 25, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it was added to the Russell 2000 ® Index when Russell Investments reconstituted its comprehensive set of U.S.
Toggle Summary Nuvectra to Present at Two Upcoming Investor Conferences
PLANO, Texas , May 17, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to present at two upcoming
Toggle Summary Nuvectra™ Reports First Quarter 2018 Financial Results
PLANO, Texas , May 02, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the first quarter ended March 31, 2018 . Highlights Reported consolidated revenues of $10.6 million for the first quarter 2018,
Toggle Summary Nuvectra™ Reports First Quarter 2018 Financial Results
PLANO, Texas , May 02, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the first quarter ended March 31, 2018 . Highlights Reported consolidated revenues of $10.6 million for the first quarter 2018,
Toggle Summary Nuvectra™ to Report First Quarter 2018 Financial Results on May 2, 2018
PLANO, Texas , April 23, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the first quarter ended March 31, 2018 on Wednesday, May 2, 2018 after market close.
Toggle Summary Nuvectra™ Reports Fourth Quarter and Full Year 2017 Financial Results
Record Quarterly Algovita® Revenue of $10.4 Million PLANO, Texas , March 06, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, today announced financial results for the fourth quarter and full year ended December 31, 2017 .
Toggle Summary Nuvectra to Present at Two Upcoming Investor Conferences
PLANO, Texas , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to present at two upcoming
Toggle Summary Nuvectra™ to Report Fourth Quarter and Full Year 2017 Financial Results on March 6, 2018
PLANO, Texas , Feb. 22, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the fourth quarter and full year ended December 31, 2017 on Tuesday, March 6, 2018 after market close.
Toggle Summary Nuvectra Secures $45 Million Second Amendment to Existing Loan and Security Agreement
Agreement Provides Company with Increased Financial Flexibility and Extended Amortization Period PLANO, Texas , Feb. 20, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it has reached an agreement with Silicon Valley Bank
Toggle Summary Nuvectra™ Announces Closing of Follow-On Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
PLANO, Texas , Feb. 05, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today the closing of its underwritten follow-on public offering of 3,248,750 shares of its common stock at a price to the public of $8.00 per share, which
Toggle Summary Nuvectra™ Announces Pricing of Follow-On Stock Offering
PLANO, Texas , Feb. 01, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today the pricing of its underwritten follow-on public offering of 2,825,000 shares of its common stock at a price to the public of $8.00 per share.
Toggle Summary Nuvectra™ Announces Proposed Follow-On Stock Offering
PLANO, Texas , Jan. 31, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it is commencing an underwritten follow-on public offering of its common stock. In addition, Nuvectra intends to grant the underwriters a 30-day
Toggle Summary Nuvectra™ Announces Preliminary Unaudited Fourth Quarter and Full Year 2017 Revenue
PLANO, Texas , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2017 . Preliminary unaudited fourth quarter consolidated revenue is
Toggle Summary Nuvectra Announces Analyst & Investor Meeting at NANS 2018
Event to Feature Leading Physician Presentations on Nuvectra’s Algovita system PLANO, Texas , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that the company will host an Analyst & Investor Meeting on Friday, January
Toggle Summary Nuvectra Achieves 1,000th Algovita® SCS System Implantation in U.S.
PLANO, Texas , Dec. 13, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that the company’s Algovita ® Spinal Cord Stimulation (SCS) system has now been implanted in 1,000 patients across the U.S.
Toggle Summary Nuvectra to Present at the 29th Annual Piper Jaffray Healthcare Conference
PLANO, Texas , Nov. 15, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to present at the 29th
Toggle Summary Nuvectra to Present at the Stifel 2017 Healthcare Conference
PLANO, Texas , Nov. 06, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to participate at the
Toggle Summary Nuvectra™ Reports Third Quarter 2017 Financial Results
Record Quarterly Algovita Revenues, Increasing to $6.3 Million PLANO, Texas , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, today announced financial results for the third quarter ended September 30, 2017 .
Toggle Summary Nuvectra to Report Third Quarter 2017 Financial Results on November 1, 2017
PLANO, Texas , Oct. 24, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the third quarter ended September 30, 2017 on Wednesday, November 1, 2017 after market close.
Toggle Summary First Spinal Cord Stimulator Implant Placed in Northern California by Dr. Goldthwaite Brings Pain Relief and Reduces Opioid Use for Local Injured Veteran
PLANO, Texas , Sept. 11, 2017 (GLOBE NEWSWIRE) -- Noel Goldthwaite , MD, senior surgeon and founding member at SpineCare Medical Group, Inc. , is the first physician in northern California to implant Nuvectra’s Algovita ® Spinal Cord Stimulation System, which successfully treated a local injured
Toggle Summary Nuvectra to Participate in Morgan Stanley Global Healthcare Conference
PLANO, Texas , Aug. 30, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & CFO, are scheduled to participate at the Morgan Stanley Global
Toggle Summary Nuvectra™ Reports Second Quarter 2017 Financial Results
Record Quarterly Algovita® Revenues, Increasing 62% Sequentially PLANO, Texas , Aug. 08, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, today announced financial results for the second quarter ended June 30, 2017 .
Toggle Summary Nuvectra to Present at the Wedbush PacGrow Healthcare Conference
PLANO, Texas , July 28, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to present at the Wedbush
Toggle Summary Nuvectra to Report Second Quarter 2017 Financial Results on August 8, 2017
PLANO, Texas , July 25, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the second quarter ended June 30, 2017 on Tuesday, August 8, 2017 after market close.
Toggle Summary Nuvectra Files Regulatory Submission with FDA for Algovita® MRI-Conditional Approval
PLANO, Texas , June 21, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it has filed its regulatory submission with the U.S. Food and Drug Administration ( FDA ) for full-body MRI-conditional approval for the Company’s
Toggle Summary Nuvectra™ Reports First Quarter 2017 Financial Results
PLANO, Texas , May 09, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the first quarter ended March 31, 2017 . Highlights Record total revenues of $5.0 million , including total Algovita sales of $3.4
Toggle Summary Nuvectra to Present at the 18th Annual B. Riley Co. Investor Conference
PLANO, Texas , May 03, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to present at the 18th
Toggle Summary Nuvectra to Report First Quarter 2017 Financial Results on May 9, 2017
PLANO, Texas , April 27, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the first quarter ended March 31, 2017 on Tuesday, May 9, 2017 after market close.
Toggle Summary Nuvectra Announces Cowen & Company Hosted Physician Panel on Spinal Cord Stimulation on March 29, 2017
Investor event will feature Q&A on SCS market and Nuvectra’s Algovita system PLANO, Texas , March 27, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Cowen and Company and The Ruth Group are hosting a physician panel on
Toggle Summary Nuvectra™ Reports Fourth Quarter and Full Year 2016 Financial Results
PLANO, Texas , March 07, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the fourth quarter and full year ended December 30, 2016 . Recent Highlights Completed FDA Premarket Approval and TUV CE mark
Toggle Summary Nuvectra to Present at the 29th Annual ROTH Conference
PLANO, Texas , March 06, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to present at the 29th
Toggle Summary Nuvectra to Present at the Cowen and Company 37th Annual Health Care Conference
PLANO, Texas , March 01, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to present at the Cowen
Toggle Summary Nuvectra to Report Fourth Quarter 2016 Financial Results on March 7, 2017
PLANO, Texas , Feb. 21, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the fourth quarter ended December 30, 2016 on Tuesday, March 7, 2017 before the market open.
Toggle Summary Nuvectra Extends Timeline of Existing Credit Facility
PLANO, Texas , Feb. 14, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it has reached an agreement with the lenders of its $45 million credit facility, Silicon Valley Bank and Oxford Finance, to extend the availability of
Toggle Summary Nuvectra to Present at the Leerink Partners 6th Annual Global Healthcare Conference
PLANO, Texas , Feb. 06, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to conduct a fireside chat
Toggle Summary Nuvectra Files Regulatory Submissions for FDA and CE Mark Approvals of the Virtis™ Sacral Nerve Stimulation (SNS) System
PLANO, Texas , Feb. 01, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it has filed regulatory submissions with the U.S. Food and Drug Administration ( FDA ) and CE Mark authorities for Virtis™, the Company’s sacral nerve
Toggle Summary Nuvectra Receives Frost & Sullivan’s New Product Innovation Award for Its Algovita® SCS System
PLANO, Texas , Jan. 17, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, has recently been named recipient of the Frost & Sullivan North American New Product Innovation Award for its leadership in the spinal cord stimulation (SCS) market.
Toggle Summary Frost & Sullivan Recognizes Nuvectra's Pioneering Spinal Cord Stimulation Product for Chronic Pain Management
The intelligent and innovative Algovita® SCS System found strong favor among physicians and patients SANTA CLARA, Calif. , Jan. 5, 2017 /PRNewswire/ -- Based on its recent analysis of the spinal cord stimulation (SCS) market, Frost & Sullivan recognizes Nuvectra with the 2017 North American New
Toggle Summary Nuvectra Corporation Signs Direct Supply Agreement
Nuvectra Signs Direct Supply Agreement with Minnetronix, Inc. for External Devices PLANO, Texas , Dec. 12, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, today announced the completion of a direct supply agreement with Minnetronix, Inc.
Toggle Summary Nuvectra to Present at the 28th Annual Piper Jaffray Healthcare Conference
PLANO, Texas , Nov. 21, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Financial Officer, are scheduled to present at the 28 th Annual Piper Jaffray
Toggle Summary Nuvectra Reports Third Quarter 2016 Financial Results
Continued Progress Building U.S. Sales Organization and Market Awareness of Algovita® System PLANO, Texas , Nov. 09, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the third quarter ended September 30,
Toggle Summary Nuvectra to Present at 7th Annual Craig-Hallum Alpha Select Conference
PLANO, Texas , Nov. 03, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Financial Officer, are scheduled to present at the 7th Annual Craig-Hallum Alpha
Toggle Summary Nuvectra to Report Third Quarter 2016 Financial Results on November 9, 2016
PLANO, Texas , Nov. 02, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the third quarter ended September 30, 2016 on Wednesday, November 9, 2016 after the market close.
Toggle Summary Nuvectra Reports Second Quarter 2016 Financial Results
Accelerating U.S. Sales Team Build and Initiated Algovita® Sales in the U.S. PLANO, Texas , Aug. 10, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the second quarter ended July 1, 2016 .
Toggle Summary Nuvectra Announces Formation of Medical Advisory Board
PLANO, Texas , Aug. 08, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today the formation of the Nuvectra Medical Advisory Board (“MAB”). The Nuvectra MAB is composed of three renowned experts in neurostimulation therapies and pain
Toggle Summary Nuvectra to Report Second Quarter 2016 Financial Results on August 10, 2016
PLANO, Texas , July 27, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the second quarter ended July 1, 2016 on Wednesday, August 10, 2016 after the market close.
Toggle Summary Nuvectra Added to the Russell Microcap® Index
PLANO, Texas , June 28, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it has been added to the Russell Microcap ®  Index. The addition occurred at the close of trading on June 24, 2016 when FTSE Russell reconstituted its
Toggle Summary Aleva Neurotherapeutics Raises USD 18 Million in Series C Financing Round
Toggle Summary Nuvectra Reports First Quarter 2016 Financial Results
PLANO, Texas , May 11, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the first quarter ended April 1, 2016 . Recent Accomplishments & Highlights Completed spin-off from Greatbatch, Inc.
Toggle Summary Nuvectra to Report First Quarter 2016 Financial Results on May 11, 2016
PLANO, Texas , April 26, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the first quarter ended April 1, 2016 , on Wednesday, May 11, 2016 after the market close.
Toggle Summary Nuvectra to Present at 15th Annual Needham Healthcare Conference
PLANO, Texas , April 11, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Financial Officer, are scheduled to present at the 15 th Annual Needham Healthcare
Toggle Summary Nuvectra Corporation Appoints Paul Hanchin as Company President
Nuvectra Announces Changes to Executive Management Team PLANO, Texas , April 07, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, today announced the appointment of Paul Hanchin in the newly created role of President, effective as of April 5,
Toggle Summary Nuvectra Corporation Begins Trading on NASDAQ
Spin-off from Greatbatch creates new stand-alone neurostimulation company PLANO, Texas , March 14, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), formerly QIG Group, LLC , announced today the completion of its spin-off from Greatbatch, Inc.
Toggle Summary Greatbatch’s Board of Directors Declares Spin-off Dividend of the Nuvectra Shares
Sets Record Date of March 7, 2016 and Nuvectra Share Distribution Date of March 14, 2016 FRISCO, Texas ,  Feb. 24, 2016  (GLOBE NEWSWIRE) --  Greatbatch, Inc.  (NYSE:GB) today announced that its Board of Directors has approved the spin-off of  QiG Group, LLC , which will convert into  Nuvectra
Toggle Summary Aleva Neurotherapeutics and Greatbatch Collaborate on Next-Generation Device for Deep Brain Stimulation (DBS)
Agreement Includes Strategic Investment in Aleva’s Current Series C Round by Greatbatch LAUSANNE ,  Switzerland ,  Feb. 01, 2016  (GLOBE NEWSWIRE) -- Aleva Neurotherapeutics, a leading company developing next-generation implants for deep brain stimulation (DBS) in major neurological indications
Toggle Summary Greatbatch, Inc. Files Form 10 for Its Proposed Nuvectra Spin-Off
FRISCO, Texas, July 30, 2015 (GLOBE NEWSWIRE) -- Greatbatch, Inc. (NYSE: GB ) today announced it has filed a Form 10 registration statement with the U.S. Securities and Exchange Commission for its proposed tax-free spin-off of its neuromodulation subsidiary, QiG Group LLC, to be known post-spin as